We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $1.5B
1-Year Est. Return 518.95%
This Fund
S&P 500
This Quarter Est. Return
+13.03%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$143M
AUM Growth
+$23.2M
Cap. Flow
+$12.2M
Cap. Flow %
8.49%
Top 10 Hldgs %
99.93%
Holding
12
New
1
Increased
1
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$14.8M
2
ANIK icon
Anika Therapeutics
ANIK
+$3.68M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$3.5M
2
EOLS icon
Evolus
EOLS
+$1.96M
3
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$691K
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$159K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$7.72B
$63.9M 44.55%
9,243,627
– –
ANIK icon
2
Anika Therapeutics
ANIK
$202M
$20.5M 14.33%
715,291
+123,616
+21% +$3.68M
LAB icon
3
Standard BioTools
LAB
$311M
$16.7M 11.67%
8,576,799
– –
EXEL icon
4
Exelixis
EXEL
$14.2B
$16.5M 11.51%
+850,000
New +$14.8M
EOLS icon
5
Evolus
EOLS
$410M
$12.9M 8.99%
1,523,484
-217,216
-12% -$1.96M
ADMA icon
6
ADMA Biologics
ADMA
$2.04B
$5.5M 3.84%
1,662,613
-1,013,480
-38% -$3.5M
VRNA
7
DELISTED
Verona Pharma
VRNA
$3.68M 2.56%
183,064
– –
SCTL
8
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.28M 0.89%
1,077,268
-525,946
-33% -$691K
EYPT icon
9
EyePoint Inc
EYPT
$1B
$1.28M 0.89%
435,298
– –
ALIM
10
DELISTED
Alimera Sciences
ALIM
$1.01M 0.7%
478,777
– –
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.14B
$99.5K 0.07%
4,333
– –
JAZZ icon
12
Jazz Pharmaceuticals
JAZZ
$16.1B
– –
-1,000
Closed -$159K

Similar funds

BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return

Caligan Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Caligan Partners held 12 positions worth $143M, up 19% from $120M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caligan Partners deployed $12.2M of net new capital in Q1 2023, opening 1 new position and adding to 1 existing holding. Its largest new stake was Exelixis: 850,000 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ADMA Biologics, an estimated $3.5M trimmed.

  • Caligan Partners's largest Q1 2023 buy was Exelixis: 850,000 shares worth $16.5M.
  • Caligan Partners added most to Anika Therapeutics in Q1 2023, an estimated $3.68M increase.
  • Caligan Partners's biggest Q1 2023 reduction was ADMA Biologics, cutting an estimated $3.5M.
  • Caligan Partners fully exited Jazz Pharmaceuticals in Q1 2023, selling an estimated $159K.
  • Caligan Partners's ten largest holdings make up 100% of its $143M portfolio in Q1 2023.
  • Caligan Partners opened 1 new position and closed 1 in Q1 2023.
  • Caligan Partners's portfolio value rose 19% quarter-over-quarter to $143M.

Based on Caligan Partners's 13F filing for Q1 2023, filed 15 May 2023.